Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibritumomab-based reduced-intensity partial T-cell-depleted allogeneic transplant with lenalidomide and DLI for relapsed DLBCL
NL-OMON36669Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2011
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan and lenalidomide in diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL), sponsored by University Medical Center Utrecht. Primary endpoint: Non-relapse mortality at 7 months. Planned start Aug 2011; status: withdrawn.
02
Drugs
ibritumomab tiuxetanlenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON36669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36669.